1921
Volume 98, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Controlled human malaria infection (CHMI) by direct venous inoculation (DVI) with 3,200 cryopreserved sporozoites (PfSPZ) consistently leads to parasitemia and malaria symptoms in malaria-naive adults. We used CHMI by DVI to investigate infection rates, parasite kinetics, and malaria symptoms in lifelong malaria–exposed (semi-immune) Gabonese adults with and without sickle cell trait. Eleven semi-immune Gabonese with normal hemoglobin (IA), nine with sickle cell trait (IS), and five nonimmune European controls with normal hemoglobin (NI) received 3,200 PfSPZ by DVI and were followed 28 days for parasitemia by thick blood smear (TBS) and quantitative polymerase chain reaction (qPCR) and for malaria symptoms. End points were time to parasitemia and parasitemia plus symptoms. PfSPZ Challenge was well tolerated and safe. Five of the five (100%) NI, 7/11 (64%) IA, and 5/9 (56%) IS volunteers developed parasitemia by TBS, and 5/5 (100%) NI, 9/11 (82%) IA, and 7/9 (78%) IS by qPCR, respectively. The time to parasitemia by TBS was longer in IA (geometric mean 16.9 days) and IS (19.1 days) than in NA (12.6 days) volunteers ( = 0.016, 0.021, respectively). Five of the five, 6/9, and 1/7 volunteers with parasitemia developed symptoms ( = 0.003, NI versus IS). Naturally adaptive immunity (NAI) to malaria significantly prolonged the time to parasitemia. Sickle cell trait seemed to prolong it further. NAI plus sickle cell trait, but not NAI alone, significantly reduced symptom rate. Twenty percent (4/20) semi-immunes demonstrated sterile protective immunity. Standardized CHMI with PfSPZ Challenge is a powerful tool for dissecting the impact of innate and naturally acquired adaptive immunity on malaria.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0343
2018-02-07
2018-07-16
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/2/tpmd170343.html?itemId=/content/journals/10.4269/ajtmh.17-0343&mimeType=html&fmt=ahah

References

  1. Sauerwein RW, Roestenberg M, Moorthy VS, , 2011. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 11: 5764.
  2. Snounou G, Pérignon J-L, , 2013. Malariotherapy–insanity at the service of malariology. Adv Parasitol 81: 223255.
  3. Bray RS, Gunders AE, Burgess RW, Freeman JB, Etzel E, Guttuso C, Colussa B, , 1962. The inoculation of semi-immune Africans with sporozoites of Laverania falcipara (Plasmodium falciparum) in Liberia. Riv Malariol 41: 199210.
  4. Beutler E, Dern RJ, Flanagan CL, , 1955. Effect of sickle-cell trait on resistance to malaria. BMJ 1: 11891191.
  5. Allison AC, , 1954. Protection afforded by sickle-cell trait against subtertian malarial infection. BMJ 1: 290294.
  6. Mordmüller B, 2015. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 14: 117.
  7. Gómez-Pérez GP, 2015. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J 14: 306.
  8. Koch R, , 1898. Berichte des geheimen medizinalrats professor Dr. R. Koch über die ergebnisse seiner forschungen in Deutsch-Ostafrika. Gesammelte Werke. Leipzig, Germany: Georg Thieme.
  9. Doolan DL, Dobaño C, Baird JK, , 2009. Acquired immunity to malaria. Clin Microbiol Rev 22: 1336.
  10. Wildling E, Winkler S, Kremsner PG, Brandts C, Jenne L, Wernsdorfer WH, , 1995. Malaria epidemiology in the province of Moyen Ogoov, Gabon. Trop Med Parasitol 46: 7782.
  11. Dal-Bianco MP, 2007. High prevalence of asymptomatic Plasmodium falciparum infection in Gabonese adults. Am J Trop Med Hyg 77: 939942.
  12. Lell B, 1999. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis Off Publ Infect Dis Soc Am 28: 794799.
  13. Lell B, Kremsner PG, , 2002. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 46: 23152320.
  14. Leigh DA, , 1981. Antibacterial activity and pharmacokinetics of clindamycin. J Antimicrob Chemother 7 (Suppl A): 39.
  15. Hoffman SL, 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97106.
  16. Planche T, Krishna S, Kombila M, Engel K, Faucher JF, Ngou-Milama E, Kremsner PG, , 2001. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 65: 599602.
  17. Hodgson SH, 2015. Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malar J 14: 33.
  18. Wampfler R, Mwingira F, Javati S, Robinson L, Betuela I, Siba P, Beck H-P, Mueller I, Felger I, , 2013. Strategies for detection of Plasmodium species gametocytes. PLoS One 8: e76316.
  19. Mordmüller B, 2017. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542: 445449.
  20. FDA, Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm. Accessed December 8, 2017.
  21. Hodgson SH, 2014. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 5: 686.
  22. Shekalaghe S, 2014. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 91: 471480.
  23. Roestenberg M, 2013. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 513.
  24. Lyke KE, 2015. Optimizing intradermal administration of cryopreserved Plasmodium falciparum sporozoites in controlled human malaria infection. Am J Trop Med Hyg 93: 12741284.
  25. Dimonte S, 2016. Sporozoite route of infection influences in vitro var gene transcription of Plasmodium falciparum parasites from controlled human infections. J Infect Dis 214: 884894.
  26. Bachmann A, 2016. Mosquito passage dramatically changes var gene expression in controlled human Plasmodium falciparum infections. PLoS Pathog 12: e1005538.
  27. Edozien JC, Gilles HM, Udeozo IOK, , 1962. Adult and cord-blood gamma-globulin and immunity to malaria in Nigerians. Lancet 280: 951955.
  28. Cohen S, McGregor IA, Carrington S, , 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192: 733737.
  29. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P, , 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45: 297308.
  30. Tall A, 2009. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission. Malar J 8: 161.
  31. Crompton PD, 2008. Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis 198: 12651275.
  32. Sokhna CS, Rogier C, Dieye A, Trape JF, , 2000. Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune population exposed to intense perennial transmission. Am J Trop Med Hyg 62: 266270.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0343
Loading
/content/journals/10.4269/ajtmh.17-0343
Loading

Data & Media loading...

Supplementary Data

Supplemental Figure and Table

  • Received : 30 Apr 2017
  • Accepted : 02 Nov 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error